<DOC>
	<DOCNO>NCT01876719</DOCNO>
	<brief_summary>This multicenter , multiple dose , randomize , double-blind , placebo-controlled , forced titration study . Patients randomize 1 4 treatment group 1:1:1:1 ratio . One-hundred twenty ( 120 ) patient plan randomize . Each patient receive AR08 ( 0.5 , 1 , 2 mg per day ) match placebo seven ( 7 ) week .</brief_summary>
	<brief_title>AR08 Treatment ADHD Children</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>1 . Meets DSMIVTR criterion primary diagnosis ADHD base structure clinical interview , MINIKID , assess Investigator 2 . Minimum score 28 ADHDRSIV Baseline 3 . Male female age 6 17 year , inclusive , time Screening 4 . Weighs â‰¥21 kg ( 46 pound ) . 5 . Is function age appropriate level intellectually , deem Investigator . 1 . Has comorbid psychiatric diagnosis ( comorbid psychiatric diagnosis establish MINIKID interview ) . 2 . Has positive response either question 4 5 Baseline /Screening version pediatric Columbia Suicide Severity Rating Scale ( CSSRS ) 3 . History daily usage ( least 28 days/month ) either antihypertensive prophylactic antimigraine medication prior Screening 4 . Current usage medication know cause QTc prolongation ADHD medication .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>AR08</keyword>
	<keyword>adrenergic receptor agonist</keyword>
	<keyword>randomize , placebo-controlled clinical trial</keyword>
</DOC>